Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 568 | 40 | 515 |
| Samples | 137 | 16 | 117 |
| Peptides | 94 | 11 | 84 |
Function
TCL1A · TCL1 family AKT coactivator A
Overexpression of the TCL1 gene in humans has been implicated in the development of mature T cell leukemia, in which chromosomal rearrangements bring the TCL1 gene in close proximity to the T-cell antigen receptor (TCR)-alpha (MIM 186880) or TCR-beta (MIM 186930) regulatory elements (summarized by Virgilio et al., 1998 [PubMed 9520462]). In normal T cells TCL1 is expressed in CD4-/CD8- cells, but not in cells at later stages of differentiation. TCL1 functions as a coactivator of the cell survival kinase AKT (MIM 164730) (Laine et al., 2000 [PubMed 10983986]).[supplied by OMIM, Jul 2010].
Isoforms & Proteins
5 transcripts · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
Gene Properties
Recurrent Mutations
All 90 amino-acid changes on canonical ENST00000402399 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in TCL1A · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in TCL1A – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| T-Cell Non-Hodgkins Lymphoma | 1/26 4% | 0/0 0% |
| Plasma Cell Myeloma | 2/44 5% | 2/305 1% |
| Melanoma | 0/210 0% | 24/1899 1% |
| Non-Small Cell Lung Carcinoma | 5/304 2% | 10/1390 1% |
| Squamous Cell Lung Carcinoma | 0/57 0% | 6/810 1% |
| Colorectal Carcinoma | 2/143 1% | 17/3239 1% |
| Germ Cell Tumour | 0/25 0% | 1/169 1% |
| B-Cell Non-Hodgkins Lymphoma | 0/88 0% | 12/2534 0% |
| Burkitts Lymphoma | 0/32 0% | 1/196 1% |
| Neuroendocrine Tumour | 0/154 0% | 3/577 1% |
| Gastric Carcinoma | 0/74 0% | 6/1809 0% |
| Endometrial Carcinoma | 1/42 2% | 1/612 0% |
| Head and Neck Carcinoma | 0/85 0% | 5/1574 0% |
| Bladder Carcinoma | 1/58 2% | 2/956 0% |
| Esophageal Squamous Cell Carcinoma | 0/51 0% | 7/2550 0% |
| Small Cell Lung Carcinoma | 0/9 0% | 2/752 0% |
| Other Solid Cancers | 0/94 0% | 4/1515 0% |
| Cervical Carcinoma | 0/35 0% | 1/422 0% |
| Glioma | 0/52 0% | 4/2127 0% |
| Pancreatic Carcinoma | 2/89 2% | 1/1611 0% |
| Thyroid Gland Carcinoma | 2/45 4% | 0/1592 0% |
| Non-Cancerous | 0/104 0% | 1/830 0% |
| Other Blood Cancers | 0/61 0% | 3/2725 0% |
| Biliary Tract Carcinoma | 0/54 0% | 1/950 0% |
| Hepatocellular Carcinoma | 0/46 0% | 2/2210 0% |
| Prostate Carcinoma | 0/13 0% | 2/2105 0% |
| Ovarian Carcinoma | 0/109 0% | 1/998 0% |
| Breast Carcinoma | 0/144 0% | 2/3264 0% |
Mutation Distribution
Where TCL1A is mutated · all tissues, split by cell line vs tissue
How many mutations in TCL1A were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 22 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 568 mutations in TCL1A
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|